These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10065709)

  • 1. Analysis of protein-protein interactions by mutagenesis: direct versus indirect effects.
    Otzen DE; Fersht AR
    Protein Eng; 1999 Jan; 12(1):41-5. PubMed ID: 10065709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant chymotrypsin inhibitor 2: expression, kinetic analysis of inhibition with alpha-chymotrypsin and wild-type and mutant subtilisin BPN', and protein engineering to investigate inhibitory specificity and mechanism.
    Longstaff C; Campbell AF; Fersht AR
    Biochemistry; 1990 Aug; 29(31):7339-47. PubMed ID: 2207109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding, proteolytic, and crystallographic analyses of mutations at the protease-inhibitor interface of the subtilisin BPN'/chymotrypsin inhibitor 2 complex.
    Radisky ES; Kwan G; Karen Lu CJ; Koshland DE
    Biochemistry; 2004 Nov; 43(43):13648-56. PubMed ID: 15504027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of amino acid residues responsible for the changes of absorption and fluorescence spectra on the binding of subtilisin BPN' and Streptomyces subtilisin inhibitor.
    Masuda-Momma K; Shimakawa T; Inouye K; Hiromi K; Kojima S; Kumagai I; Miura K; Tonomura B
    J Biochem; 1993 Dec; 114(6):906-11. PubMed ID: 8138550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing subtilisin BPN' to cleave substrates containing dibasic residues.
    Ballinger MD; Tom J; Wells JA
    Biochemistry; 1995 Oct; 34(41):13312-9. PubMed ID: 7577915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Context dependence of protein secondary structure formation: the three-dimensional structure and stability of a hybrid between chymotrypsin inhibitor 2 and helix E from subtilisin Carlsberg.
    Osmark P; Sørensen P; Poulsen FM
    Biochemistry; 1993 Oct; 32(41):11007-14. PubMed ID: 8218165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the intramolecular hydrogen bond network in the inhibitory power of chymotrypsin inhibitor 2.
    Radisky ES; Lu CJ; Kwan G; Koshland DE
    Biochemistry; 2005 May; 44(18):6823-30. PubMed ID: 15865427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel peptide inhibitor of subtilisin BPN'.
    Ishida K; Shimizu M; Wakasugi A; Matsui Y; Nakamura A; Kojima S
    FEBS Open Bio; 2022 Nov; 12(11):2057-2064. PubMed ID: 36053920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An engineered disulfide cross-link accelerates the refolding rate of calcium-free subtilisin by 850-fold.
    Strausberg S; Alexander P; Wang L; Gallagher T; Gilliland G; Bryan P
    Biochemistry; 1993 Oct; 32(39):10371-7. PubMed ID: 8399180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energetics of folding subtilisin BPN'.
    Bryan P; Alexander P; Strausberg S; Schwarz F; Lan W; Gilliland G; Gallagher DT
    Biochemistry; 1992 Jun; 31(21):4937-45. PubMed ID: 1599918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of residues in the reactive site loop of chymotrypsin inhibitor 2 to protein stability and activity.
    Jackson SE; Fersht AR
    Biochemistry; 1994 Nov; 33(46):13880-7. PubMed ID: 7947796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of a stabilizing Ca(2+)-binding loop into subtilisin BPN'.
    Braxton S; Wells JA
    Biochemistry; 1992 Sep; 31(34):7796-801. PubMed ID: 1510966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furilisin: a variant of subtilisin BPN' engineered for cleaving tribasic substrates.
    Ballinger MD; Tom J; Wells JA
    Biochemistry; 1996 Oct; 35(42):13579-85. PubMed ID: 8885837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular recognition at the active site of subtilisin BPN': crystallographic studies using genetically engineered proteinaceous inhibitor SSI (Streptomyces subtilisin inhibitor).
    Takeuchi Y; Noguchi S; Satow Y; Kojima S; Kumagai I; Miura K; Nakamura KT; Mitsui Y
    Protein Eng; 1991 Jun; 4(5):501-8. PubMed ID: 1891457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering a novel specificity in subtilisin BPN'.
    Rheinnecker M; Baker G; Eder J; Fersht AR
    Biochemistry; 1993 Feb; 32(5):1199-203. PubMed ID: 8448130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein-protein interactions as a tool for site-specific labeling of proteins.
    Jäger M; Michalet X; Weiss S
    Protein Sci; 2005 Aug; 14(8):2059-68. PubMed ID: 15987886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilizing the subtilisin BPN' pro-domain by phage display selection: how restrictive is the amino acid code for maximum protein stability?
    Ruan B; Hoskins J; Wang L; Bryan PN
    Protein Sci; 1998 Nov; 7(11):2345-53. PubMed ID: 9828000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large increases in general stability for subtilisin BPN' through incremental changes in the free energy of unfolding.
    Pantoliano MW; Whitlow M; Wood JF; Dodd SW; Hardman KD; Rollence ML; Bryan PN
    Biochemistry; 1989 Sep; 28(18):7205-13. PubMed ID: 2684274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strain in the folding nucleus of chymotrypsin inhibitor 2.
    Ladurner AG; Itzhaki LS; Fersht AR
    Fold Des; 1997; 2(6):363-8. PubMed ID: 9427010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of the hydrophobic core in the transition state for folding of chymotrypsin inhibitor 2: a critical test of the protein engineering method of analysis.
    Jackson SE; elMasry N; Fersht AR
    Biochemistry; 1993 Oct; 32(42):11270-8. PubMed ID: 8218192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.